---
document_datetime: 2025-12-09 23:29:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-sandoz.html
document_name: pregabalin-sandoz.html
version: success
processing_time: 0.1330283
conversion_datetime: 2025-12-26 17:10:39.648207
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pregabalin Sandoz

[RSS](/en/individual-human-medicine.xml/66834)

##### Authorised

This medicine is authorised for use in the European Union

pregabalin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pregabalin Sandoz](#news-on)
- [More information on Pregabalin Sandoz](#more-information-on-pregabalin-sandoz-1440)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Pregabalin Sandoz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pregabalin Sandoz.

For practical information about using Pregabalin Sandoz, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Pregabalin Sandoz and what is it used for?

Pregabalin Sandoz is a medicine used to treat adults with the following conditions:

- neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury;
- epilepsy, where it is used as an 'add-on' to existing treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment;
- generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).

Pregabalin Sandoz is a 'generic medicine'. This means that Pregabalin Sandoz is similar to a 'reference medicine' already authorised in the European Union (EU) called Lyrica.

Pregabalin Sandoz contains the active substance pregabalin.

## How is Pregabalin Sandoz used?

Pregabalin Sandoz is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription. The recommended starting dose is 150 mg per day, divided into two or three doses. After three to seven days, the dose can be increased to 300 mg per day. Doses can be increased up to twice more until the most effective dose is reached. The maximum dose is 600 mg per day. Stopping treatment with Pregabalin Sandoz should also be done gradually, over at least a week. Doctors may need to lower the dose in patients who have kidney problems.

## How does Pregabalin Sandoz work?

The active substance in Pregabalin Sandoz, pregabalin, is similar in structure to the body's own 'neurotransmitter' gamma?amino butyric acid (GABA), but has very different biological effects. Neurotransmitters are chemicals that allow nerve cells to communicate with each other. The exact way that pregabalin works is not fully understood, but it is thought to affect the way that calcium enters nerve cells. This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in pain, epilepsy and anxiety.

## How has Pregabalin Sandoz been studied?

Because Pregabalin Sandoz is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Lyrica. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Pregabalin Sandoz?

Because Pregabalin Sandoz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Pregabalin Sandoz approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Sandoz has been shown to have comparable quality and to be bioequivalent to Lyrica. Therefore, the CHMP's view was that, as for Lyrica, the benefit outweighs the identified risk. The Committee recommended that Pregabalin Sandoz be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pregabalin Sandoz?

A risk management plan has been developed to ensure that Pregabalin Sandoz is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pregabalin Sandoz, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the [Pregabalin Sandoz : EPAR - Risk management plan](/en/documents/rmp/pregabalin-sandoz-epar-risk-management-plan_en.pdf) .

## Other information about Pregabalin Sandoz

The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Sandoz on 19 June 2015.

For more information about treatment with Pregabalin Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Pregabalin Sandoz : EPAR - Summary for the public

Reference Number: EMA/277953/2015

English (EN) (121.37 KB - PDF)

**First published:** 16/07/2015

**Last updated:** 16/07/2015

[View](/en/documents/overview/pregabalin-sandoz-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-168)

български (BG) (126.74 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/bg/documents/overview/pregabalin-sandoz-epar-summary-public_bg.pdf)

español (ES) (103.09 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/es/documents/overview/pregabalin-sandoz-epar-summary-public_es.pdf)

čeština (CS) (123.18 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/cs/documents/overview/pregabalin-sandoz-epar-summary-public_cs.pdf)

dansk (DA) (103.04 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/da/documents/overview/pregabalin-sandoz-epar-summary-public_da.pdf)

Deutsch (DE) (103.9 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/de/documents/overview/pregabalin-sandoz-epar-summary-public_de.pdf)

eesti keel (ET) (101.53 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/et/documents/overview/pregabalin-sandoz-epar-summary-public_et.pdf)

ελληνικά (EL) (128.47 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/el/documents/overview/pregabalin-sandoz-epar-summary-public_el.pdf)

français (FR) (103.32 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/fr/documents/overview/pregabalin-sandoz-epar-summary-public_fr.pdf)

hrvatski (HR) (118.33 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/hr/documents/overview/pregabalin-sandoz-epar-summary-public_hr.pdf)

italiano (IT) (102.92 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/it/documents/overview/pregabalin-sandoz-epar-summary-public_it.pdf)

latviešu valoda (LV) (118.44 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/lv/documents/overview/pregabalin-sandoz-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (120.67 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/lt/documents/overview/pregabalin-sandoz-epar-summary-public_lt.pdf)

magyar (HU) (119.62 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/hu/documents/overview/pregabalin-sandoz-epar-summary-public_hu.pdf)

Malti (MT) (123.57 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/mt/documents/overview/pregabalin-sandoz-epar-summary-public_mt.pdf)

Nederlands (NL) (103.6 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/nl/documents/overview/pregabalin-sandoz-epar-summary-public_nl.pdf)

polski (PL) (122.77 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/pl/documents/overview/pregabalin-sandoz-epar-summary-public_pl.pdf)

português (PT) (102.73 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/pt/documents/overview/pregabalin-sandoz-epar-summary-public_pt.pdf)

română (RO) (118.44 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/ro/documents/overview/pregabalin-sandoz-epar-summary-public_ro.pdf)

slovenčina (SK) (122.67 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/sk/documents/overview/pregabalin-sandoz-epar-summary-public_sk.pdf)

slovenščina (SL) (117.21 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/sl/documents/overview/pregabalin-sandoz-epar-summary-public_sl.pdf)

Suomi (FI) (101.96 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/fi/documents/overview/pregabalin-sandoz-epar-summary-public_fi.pdf)

svenska (SV) (101.72 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

16/07/2015

[View](/sv/documents/overview/pregabalin-sandoz-epar-summary-public_sv.pdf)

Pregabalin Sandoz : EPAR - Risk management plan

English (EN) (255.77 KB - PDF)

**First published:** 16/07/2015

**Last updated:** 06/10/2025

[View](/en/documents/rmp/pregabalin-sandoz-epar-risk-management-plan_en.pdf)

## Product information

Pregabalin Sandoz : EPAR - Product Information

English (EN) (521.12 KB - PDF)

**First published:** 16/07/2015

**Last updated:** 02/12/2025

[View](/en/documents/product-information/pregabalin-sandoz-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-462)

български (BG) (626.94 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/bg/documents/product-information/pregabalin-sandoz-epar-product-information_bg.pdf)

español (ES) (529.64 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/es/documents/product-information/pregabalin-sandoz-epar-product-information_es.pdf)

čeština (CS) (551.14 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/cs/documents/product-information/pregabalin-sandoz-epar-product-information_cs.pdf)

dansk (DA) (461.02 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/da/documents/product-information/pregabalin-sandoz-epar-product-information_da.pdf)

Deutsch (DE) (519.56 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/de/documents/product-information/pregabalin-sandoz-epar-product-information_de.pdf)

eesti keel (ET) (497.91 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/et/documents/product-information/pregabalin-sandoz-epar-product-information_et.pdf)

ελληνικά (EL) (641.89 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/el/documents/product-information/pregabalin-sandoz-epar-product-information_el.pdf)

français (FR) (633.42 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/fr/documents/product-information/pregabalin-sandoz-epar-product-information_fr.pdf)

hrvatski (HR) (575.63 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/hr/documents/product-information/pregabalin-sandoz-epar-product-information_hr.pdf)

íslenska (IS) (722.9 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/is/documents/product-information/pregabalin-sandoz-epar-product-information_is.pdf)

italiano (IT) (591.25 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/it/documents/product-information/pregabalin-sandoz-epar-product-information_it.pdf)

latviešu valoda (LV) (631.2 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/lv/documents/product-information/pregabalin-sandoz-epar-product-information_lv.pdf)

lietuvių kalba (LT) (530.1 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/lt/documents/product-information/pregabalin-sandoz-epar-product-information_lt.pdf)

magyar (HU) (568.86 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/hu/documents/product-information/pregabalin-sandoz-epar-product-information_hu.pdf)

Malti (MT) (566.36 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/mt/documents/product-information/pregabalin-sandoz-epar-product-information_mt.pdf)

Nederlands (NL) (511.89 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/nl/documents/product-information/pregabalin-sandoz-epar-product-information_nl.pdf)

norsk (NO) (503.73 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/no/documents/product-information/pregabalin-sandoz-epar-product-information_no.pdf)

polski (PL) (571.5 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/pl/documents/product-information/pregabalin-sandoz-epar-product-information_pl.pdf)

português (PT) (498.4 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/pt/documents/product-information/pregabalin-sandoz-epar-product-information_pt.pdf)

română (RO) (577.3 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/ro/documents/product-information/pregabalin-sandoz-epar-product-information_ro.pdf)

slovenčina (SK) (558.54 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/sk/documents/product-information/pregabalin-sandoz-epar-product-information_sk.pdf)

slovenščina (SL) (523.88 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/sl/documents/product-information/pregabalin-sandoz-epar-product-information_sl.pdf)

Suomi (FI) (512.89 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/fi/documents/product-information/pregabalin-sandoz-epar-product-information_fi.pdf)

svenska (SV) (497.65 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

02/12/2025

[View](/sv/documents/product-information/pregabalin-sandoz-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000313464 02/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pregabalin Sandoz : EPAR - All Authorised presentations

English (EN) (77.12 KB - PDF)

**First published:** 16/07/2015

**Last updated:** 10/08/2021

[View](/en/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-254)

български (BG) (112.62 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/bg/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_bg.pdf)

español (ES) (71.22 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/es/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_es.pdf)

čeština (CS) (88.97 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/cs/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (69.55 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/da/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (77.14 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/de/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (100.29 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/et/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (112.33 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/el/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_el.pdf)

français (FR) (78.78 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/fr/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (88.95 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/hr/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (70.38 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/is/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_is.pdf)

italiano (IT) (70.75 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/it/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (91.26 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/lv/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (125.94 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/lt/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (106.76 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/hu/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (94.92 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/mt/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (69.65 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/nl/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (69.39 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/no/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_no.pdf)

polski (PL) (94.14 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/pl/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_pl.pdf)

português (PT) (70.1 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/pt/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_pt.pdf)

română (RO) (90.4 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/ro/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (88.1 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/sk/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (87.27 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/sl/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (71.64 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/fi/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (70.21 KB - PDF)

**First published:**

16/07/2015

**Last updated:**

10/08/2021

[View](/sv/documents/all-authorised-presentations/pregabalin-sandoz-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pregabalin Sandoz Active substance pregabalin International non-proprietary name (INN) or common name pregabalin Therapeutic area (MeSH)

- Anxiety Disorders
- Neuralgia
- Epilepsy

Anatomical therapeutic chemical (ATC) code N02BF02

### Pharmacotherapeutic group

Other analgesics and antipyretics

### Therapeutic indication

**Neuropathic pain**

Pregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.

**Epilepsy**

Pregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

**Generalised Anxiety Disorder**

Pregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

## Authorisation details

EMA product number EMEA/H/C/004010

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Sandoz GmbH

Biochemiestr. 10

Opinion adopted 23/04/2015 Marketing authorisation issued 19/06/2015 Revision 23

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pregabalin Sandoz : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (160.74 KB - PDF)

**First published:** 16/05/2024

**Last updated:** 02/12/2025

[View](/en/documents/procedural-steps-after/pregabalin-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Pregabalin Sandoz : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (198.57 KB - PDF)

**First published:** 26/11/2015

**Last updated:** 16/05/2024

[View](/en/documents/procedural-steps-after/pregabalin-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Pregabalin Sandoz : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/102862/2015

English (EN) (312.34 KB - PDF)

**First published:** 16/07/2015

**Last updated:** 16/07/2015

[View](/en/documents/assessment-report/pregabalin-sandoz-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pregabalin Sandoz

Adopted

Reference Number: EMA/CHMP/242142/2015

English (EN) (66.23 KB - PDF)

**First published:** 24/04/2015

**Last updated:** 24/04/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-sandoz_en.pdf)

#### News on Pregabalin Sandoz

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-april-2015) 24/04/2015

#### More information on Pregabalin Sandoz

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-517)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/12/2025

## Share this page

[Back to top](#main-content)